Skip to main content

REVIEW article

Front. Oncol.
Sec. Cardio-Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1492203

Review of the Clinical Status of Cardiotoxicity of HER-2 Positive Breast Cancer Targeted Therapeutic Drugs

Provisionally accepted
Zhang Xiang Zhang Xiang 1Yulian Yin Yulian Yin 1Qiuting YU Qiuting YU 1*Xinlin Chen Xinlin Chen 2*Yiqin Cheng Yiqin Cheng 1*
  • 1 Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality, China
  • 2 Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the survival rate of HER-2-positive breast cancer patients. However, in clinical applications, this type of targeted drugs exhibits varying degrees of cardiotoxicity, and the mechanism of their cardiotoxicity is currently unclear. In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). We list the evidence of cardiotoxicity for various drugs based on current clinical trials and summarize their corresponding epidemiological profiles. We also discuss the regulation of cardiotoxicity from three perspectives: clinical biomarkers of cardiotoxicity, permissive cardiotoxicity, and the current status of cardiotoxicity regulation.

    Keywords: breast cancer, HER-2, cardiotoxicity, targeted therapy, review

    Received: 06 Sep 2024; Accepted: 30 Dec 2024.

    Copyright: © 2024 Xiang, Yin, YU, Chen and Cheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Qiuting YU, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality, China
    Xinlin Chen, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, Shanghai Municipality, China
    Yiqin Cheng, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Shanghai Municipality, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.